Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
platelet-derived exosome product
- Development stage
- Phase 1
- Lead developer
- RION
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation, Topical
01
Overview
Platelet-derived exosome product (PEP) is an exosome-based therapeutic developed by Rion Inc, consisting of extracellular vesicles derived from human platelets. PEP is designed to leverage the regenerative and anti-inflammatory properties of platelet-derived factors. In preclinical models of chronic obstructive pulmonary disease (COPD) and emphysema, nebulized PEP has demonstrated the ability to attenuate lung inflammation and promote tissue homeostasis. Its mechanism involves modulating the lung microenvironment by downregulating pro-inflammatory signaling pathways, such as Thy1-ITGAX/ITGB2, and upregulating reparative pathways like Lamc1-CD44. This orchestration induces a phenotypic switch in alveolar macrophages from a pro-inflammatory state to a reparative M2 state, thereby suppressing the production of tumor necrosis factor (TNF) and other inflammatory mediators. PEP is also being investigated for its potential in wound healing and other regenerative medicine applications.
- Other names
- Purified Exosome Product
02
Targets
CD44 (CD44 antigen)ITGAX (Integrin alpha-X)ITGB2 (Complement receptor 4)LN (Laminin family)THY1 (CD90)
Beyond the preview
Go deeper on platelet-derived exosome product.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on platelet-derived exosome product.